Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer
Background and purpose: Neoadjuvant therapy (NAT) has become standard therapy for early triple-negative breast cancer (TNBC). The aim of this study was to report real-world outcome of TNBC treated with NAT with or without pembrolizumab and to identify predictive factors for achieving pathologic comp...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Medical Journals Sweden
2026-02-01
|
| Серія: | Acta Oncologica |
| Предмети: | |
| Онлайн доступ: | https://actaoncologica.se/actaoncologica/article/view/44896 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|